Core Viewpoint - Both Nuo Cheng Jian Hua and Bai Ao Sai Tu have released their performance forecasts for 2025, indicating significant revenue growth and profitability improvements for both companies. Nuo Cheng Jian Hua - Nuo Cheng Jian Hua expects to achieve an annual revenue of approximately 2.365 billion yuan, representing a growth of around 134% compared to the previous year [2] - The company anticipates a net profit attributable to shareholders of approximately 633 million yuan, an increase of about 1.074 billion yuan year-on-year [2] - The net profit attributable to shareholders after excluding non-recurring gains and losses is expected to be around 534 million yuan, an increase of approximately 974 million yuan compared to the previous year [2] - The main reasons for the performance change include: 1) Continuous rapid growth in drug revenue, driven by the approval of new indications for drugs like Acalabrutinib and the launch of new treatments [4][13] 2) Growth in business development (BD) revenue, with two BD transactions completed in 2025 [5][15] - Historical financial performance shows that Nuo Cheng Jian Hua will achieve profitability for the first time in 2025, having previously reported losses in the years 2021 to 2024 [6][15] Bai Ao Sai Tu - Bai Ao Sai Tu expects to achieve an annual revenue between 1.3688 billion and 1.3888 billion yuan, an increase of 388.4 million to 408.4 million yuan year-on-year, representing a growth of 39.61% to 41.65% [7] - The company anticipates a net profit attributable to shareholders between 162.4 million and 182.4 million yuan, an increase of 128.9 million to 148.9 million yuan year-on-year, reflecting a growth of 384.26% to 443.88% [7] - The net profit attributable to shareholders after excluding non-recurring gains and losses is expected to be between 104.9 million and 124.9 million yuan, an increase of 81.9 million to 101.9 million yuan year-on-year, indicating a growth of 356.81% to 443.88% [7] - The main reasons for the performance change include: 1) Benefits from the continuous expansion into overseas markets and the recovery of the domestic biopharmaceutical industry [9][18] 2) High barriers to technology ensuring high gross margins and improved operational efficiency through lean management initiatives [9][18] - Historical financial performance indicates that Bai Ao Sai Tu will achieve profitability for the second consecutive year in 2025, following a previous loss in 2021 and a small profit in 2024 [10][18]